Arndt Vogel

机构：Università Campus Bio-Medico, Toronto General Hospital, Princess Margaret Cancer Centre, Medizinische Hochschule Hannover

发表论文 12 篇 · 总被引 83 次 · h-index 4

代表论文

• Camrelizumab plus rivoceranib vs sorafenib as first-line therapy for unresectable hepatocellular carcinoma (uHCC): Final overall survival analysis of the phase 3 CARES-310 study. (2024 · Journal of Clinical Oncology · 被引 35)
• Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study (2025 · The Lancet Oncology · 被引 25)
• Durvalumab in Advanced Biliary Tract Cancer: Real‐World Data From a Large Cohort of Patients Across Multiple International Centers (2025 · Liver International · 被引 10)
• Negative impact of corticosteroid use on outcome in patients with advanced BTCs treated with cisplatin, gemcitabine, and durvalumab: A large real‐life worldwide population (2025 · International Journal of Cancer · 被引 4)
• The impact of molecular alterations in patients with advanced biliary tract cancer receiving cisplatin, gemcitabine, and durvalumab: a large, real-life, worldwide population (2025 · JNCI Journal of the National Cancer Institute · 被引 4)
• Factors associated with reaching maintenance therapy in patients with advanced biliary tract cancer treated with durvalumab: Real‐world results from a multicenter and multinational study (2025 · International Journal of Cancer · 被引 4)